Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 7/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.59 |
| ▸ | POLB | P06746 | 6/20 | 0.57 |
| ▸ | GSK3A | P49840 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.51 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.51 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.51 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.51 |
| ▸ | DHX29 | Q7Z478 | 1/20 | 0.51 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896679 | 1.00 | APEX1 (0.66) | APEX1PIK3CGMEN1KMT2APOLB | |
| SCHEMBL30089282 | 1.00 | APEX1 (0.66) | APEX1PIK3CGMEN1KMT2APOLB | |
| SCHEMBL3899841 | 0.89 | STAT3 (0.63) | APEX1MEN1KMT2APOLBRAB9A | |
| SCHEMBL3899838 | 0.89 | STAT3 (0.63) | APEX1MEN1KMT2APOLBRAB9A | |
| SCHEMBL13220180 | 0.88 | MEN1 (0.69) | PIK3CGMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL2896716 | 0.88 | MEN1 (0.69) | PIK3CGMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL2898197 | 0.88 | MEN1 (0.69) | PIK3CGMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL2898198 | 0.88 | MEN1 (0.69) | PIK3CGMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL2897863 | 0.88 | MEN1 (0.69) | PIK3CGMEN1KMT2APOLBL3MBTL1 | |
| SCHEMBL2896709 | 0.88 | MEN1 (0.69) | PIK3CGMEN1KMT2APOLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | claimed |
| WO-2005041951-A2 | RHODANINE DERIVATIVES FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | claimed |
| US-7566732-B2 | Rhodanine compositions for use as antiviral agents | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | RIGEL PHARMACEUTICALS, INC. (US) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276520-A1 | Rhodanine derivatives and pharmaceutical compositions containing them | UBQLN1, UBQLN2, UBE2G2 | APEX1 1572/4885PIK3CG 759/4885MEN1 1562/4885 |
| US-20090137644-A1 | RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS | RBX1, ITCH, UBQLN1 | APEX1 888/4885PIK3CG 559/4885MEN1 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.